A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
第一作者:
C,Kollmannsberger
第一单位:
Department of Hematology/Oncology, University of Tuebingen, Germany.
作者:
医学主题词
成年人(Adult);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);剂量效应关系, 药物(Dose-Response Relationship, Drug);女(雌)性(Female);人类(Humans);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);紫杉酚(Paclitaxel)
DOI
10.1093/annonc/mdl042
PMID
16533873
发布时间
2020-02-03
- 浏览4
Annals of oncology
1007-13页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



